>> Don't tell me. >> The new members of the Advisory Committee on Immunization Practices will continue their first meeting later today. The seven newly appointed members of the panel discussed childhood vaccines yesterday.And joining us now ahead of day two is former FDA Commissioner Scott Gottlieb, who served in the first Trump administration. He's a board member with Pfizer and Illumina and a CNBC contributor. And Doctor Gottlieb, thanks for being here.Thanks a lot. So walk us through what this means. The ...

Company Overview - GeneDx Holdings Corp. is a biotechnology company that specializes in clinical diagnostic services for rare and pediatric genetic disorders [3]. Allegations of Wrongdoing - Grizzly Research published a report on February 5, 2025, alleging that GeneDx is committing widespread fraud, claiming that the company's growth is largely an illusion driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue [4]. - The report accuses GeneDx of using an illegal practice known as "code stacking" to inflate its revenue [4]. - It is suggested that GeneDx executives, including CEO Katherine Stueland and CFO Kevin Feeley, may be aware of imminent risks, as they have consistently sold their shares immediately upon vesting without engaging in open market purchases [4]. Stock Market Reaction - Following the publication of the report, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [4].

Core Viewpoint - Aveanna Healthcare Holdings Inc. has completed the acquisition of Thrive Skilled Pediatric Care, enhancing its position in the pediatric home care market and expanding its service offerings into new states [1][2][3]. Company Overview - Aveanna Healthcare is a diversified home care platform providing services to medically complex, high-cost patient populations, with a presence in 36 states [7]. - The company offers a wide range of healthcare services, including nursing, rehabilitation, therapy, and case management, aimed at providing high-quality, lower-cost alternatives to prolonged hospitalization [7]. Acquisition Details - Thrive SPC is one of the largest independent providers of pediatric home care, operating 23 locations across seven states [2]. - The acquisition is expected to create significant growth opportunities for Aveanna, reinforcing its commitment to clinical excellence and compassionate care [3]. - The deal was financed through a combination of common stock and cash [3]. Strategic Implications - The integration of Thrive SPC is anticipated to enhance Aveanna's existing footprint and introduce its specialized care model into two new states [2][3]. - The acquisition aligns with Aveanna's strategic mission to lead in delivering high-quality care while providing value and clinical innovation to payors and stakeholders [3]. Advisory and Legal Support - Edge Healthcare Partners acted as the financial advisor for Aveanna, while Cantor Fitzgerald & Co. served as the financial advisor for Thrive SPC [4]. - Legal counsel for Aveanna was provided by Bass, Berry & Sims, and Ropes & Gray LLP represented Thrive SPC [4].

Pediatrix Medical Group, Inc. (MD) is strategically positioned to grow on the back of delivering high-quality, evidence-based care in the healthcare space. The company has gained 5.6% in the year-to-date (YTD) period, outperforming the industry average of a 6.4% fall.Pediatrix Medical — with a market cap of $1.2 billion — is a physician services provider company headquartered in Sunrise, FL. It provides newborn, maternal-fetal, radiology, pediatric cardiology and other pediatric subspecialties physician ser ...

Vivos Therapeutics (VVOS) Q1 2025 Earnings Call May 15, 2025 05:00 PM ET Company Participants Brad Amman - CFOKirk Huntsman - Chairman & CEO Conference Call Participants Do Kim - Senior Biotech AnalystLucas Ward - Senior Research Analyst Operator Good day, everyone, and welcome to the Vivo Therapeutics First Quarter twenty twenty five Earnings Call. At this time, participants are in a listen only mode. A question and answer session will follow management's remarks. This conference call is being recorded and ...

Summary of Aviana Healthcare Conference Call Company Overview - **Company**: Aviana Healthcare - **Industry**: Home Care Services - **CEO**: Jeff Shaner - **CFO**: Matt Buckhalter - **Key Focus**: Strategic transformation and growth in home care services, including pediatric, adult, and geriatric care [3][5] Core Insights and Arguments - **Market Position**: Aviana is a leading national provider of home care services with over 340 locations across 34 states, serving over 80,000 patients weekly [4][6] - **Growth Strategy**: The company aims to enhance partnerships with government and preferred payers, identify cost efficiencies, modernize medical solutions, manage capital structure, and engage employees [10][12][13] - **Revenue Growth**: Aviana expects 2025 revenue to exceed $2.15 billion and adjusted EBITDA to exceed $207 million, reflecting a strong growth trajectory [8] - **Preferred Payer Agreements**: The goal is to increase preferred payer agreements from 22 to 30 by 2025, with a current mix of 54% in managed care organization volumes [14][15] - **Episodic Payer Mix**: The company aims to maintain an episodic payer mix above 70%, achieving 77% in Q1 2025 [19] Financial Performance - **Q1 Financials**: Revenues rose 14% year-over-year, with private duty services leading at 16.5% organic growth [27] - **Adjusted EBITDA**: Increased by 93.1% year-over-year to $67.4 million, driven by payer relations and government affairs strategies [28] - **Capital Structure**: Maintains liquidity of over $260 million and has $1.47 billion in variable rate debt, mostly hedged [29][30] Strategic Initiatives - **Acquisition Plans**: Recently announced plans to acquire Thrive Skilled Pediatric Care, expanding pediatric services into New Mexico and Kansas [6][7] - **Value-Based Agreements**: Focus on enhancing reimbursement rates and adding value-based agreements to improve clinical outcomes and attract caregivers [16] - **Legislative Advocacy**: Aiming to improve reimbursement rates in at least 10 states and advocate for Medicaid rate integrity for children with complex medical conditions [17][18] Additional Important Points - **Demand for Services**: The industry does not face a demand problem, with strong interest from state and federal governments for home and community-based care solutions [13] - **Long-Term Outlook**: Aviana is optimistic about its future, emphasizing cost-effective, patient-preferred solutions that align with payer and government interests [22][31]

Aytu Biopharma (AYTU) Q3 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum, Investor Relations at Robert, your line, you may begin. Speaker1 Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal twenty twenty five third quarter operational and financial results for the period ended 03/31/2025. With us on tod ...

Core Insights - The Leukemia & Lymphoma Society (LLS) has partnered with Kroger's Dallas Division to raise funds for The Dare to Dream Project, aimed at improving treatments for pediatric blood cancer patients and providing support for their families [1][2][4] Group 1: The Dare to Dream Project - The Dare to Dream Project is a $175 million campaign focused on funding pediatric blood cancer research, advocating for healthcare policy changes, and expanding support services for affected children and families [8] - Only 5% of cancer drugs have been approved for first-time use in children, and 80% of childhood cancer survivors face chronic health issues due to their treatments [3] Group 2: Fundraising Efforts - From May 14 to June 3, 2025, Kroger encourages customers to donate at checkout in 110 stores across North and East Texas and Louisiana to support LLS's Dare to Dream Project [2] - Funds raised will exclusively benefit the life-saving work of The Dare to Dream Project, helping to ensure better treatment outcomes for children with blood cancer [1][2] Group 3: LLS's Commitment - LLS is pioneering pediatric blood cancer research, including the establishment of the first-ever pediatric AML Data Commons and the launch of the LLS PedAL Master Clinical Trial [4] - The organization has been dedicated to improving the quality of life for blood cancer patients and their families for over 75 years [6]

CeriBell (CBLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations AssociateJane Chao - Co-Founder, President, CEO & DirectorScott Blumberg - Chief Financial OfficerStephanie Piazzola - VP - Equity ResearchRohin Patel - Vice PresidentJoshua Jennings - Managing DirectorJohn Young - Director - Healthcare Equity ResearchJeffrey Cohen - MD - Equity Research Conference Call Participants Margaret Kaczor Andrew - Research Analyst - Healthcare Operator thank ...

Core Insights - Aveanna Healthcare Holdings Inc. reported strong financial results for Q1 2025, with revenue growth of 14.0% and adjusted EBITDA growth of 93.1% compared to the same period last year [2][8][10] - The company is optimistic about its strategic transformation and has raised its full-year 2025 revenue guidance to over $2.15 billion and adjusted EBITDA guidance to over $207 million [10][11] Financial Performance - Revenue for the three-month period ended March 29, 2025, was $559.2 million, up from $490.7 million for the same period in 2024, representing an increase of $68.6 million [3][30] - Gross margin increased to $183.6 million, or 32.8% of revenue, compared to $145.9 million, or 29.7% of revenue, for the prior year, marking a 25.9% increase [4][30] - Net income for the quarter was $5.2 million, a significant turnaround from a net loss of $11.2 million in the same quarter of 2024 [5][31] - Adjusted EBITDA reached $67.4 million, or 12.0% of revenue, compared to $34.9 million, or 7.1% of revenue, for the same period last year, reflecting a 93.1% increase [6][30] Segment Performance - The PDS segment saw a revenue increase of $65.0 million, while the HHH and MS segments contributed $2.1 million and $1.5 million increases, respectively [3][30] - The Field contribution margin improved to 16.5% from 11.8% year-over-year, indicating enhanced operational efficiency [30][34] Cash Flow and Liquidity - As of March 29, 2025, the company had cash of $71.5 million and an incremental borrowing capacity of $56.2 million under its securitization facility [9][29] - Free cash flow for the quarter was $(12.9) million, reflecting cash used in operating activities of $(8.6) million [9][24] Strategic Outlook - The company emphasizes the importance of government and payor partnerships in driving core volume growth and clinical outcomes [2][10] - Aveanna's management is confident in the company's trajectory, citing strategic cost reductions and improved reimbursement rates as key drivers of performance [10][11]